Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib

被引:21
|
作者
Chen, Zhen [1 ,2 ]
Yu, Danlei [1 ,2 ]
Owonikoko, Taofeek K. [3 ,4 ]
Ramalingam, Suresh S. [1 ,2 ]
Sun, Shi-Yong [1 ,2 ]
机构
[1] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[2] Winship Canc Inst, Atlanta, GA 30322 USA
[3] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA
[4] Hillman Canc Ctr, Pittsburgh, PA USA
关键词
FATTY-ACID SYNTHESIS; THERAPEUTIC-EFFICACY; ACQUIRED-RESISTANCE; LIPID-METABOLISM; INHIBITION; AZD9291; GROWTH; BIM;
D O I
10.1038/s41388-021-02057-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Emergence of acquired resistance to osimertinib (AZD9291), the first-approved third-generation EGFR inhibitor that selectively and irreversibly inhibits the activating EGFR mutations and the resistant T790M mutation, is a giant and urgent clinical challenge. Fully understanding the biology underlying the response of EGFR mutant non-small cell lung cancer (NSCLC) to osimertinib is the foundation for development of mechanism-driven strategies to overcome acquired resistance to osimertinib or other third-generation EGFR inhibitors. This study focused on tackling this important issue by elucidating the critical role of sterol regulatory element-binding protein 1 (SREBP1) degradation in conferring the response of EGFR mutant NSCLC cells to osimertinib and by validating the strategy via directly targeting SREBP1 for overcoming osimertinib acquired resistance. Osimertinib facilitated degradation of the mature form of SREBP1 (mSREBP1) in a GSK3/FBXW7-dependent manner and reduced protein levels of its regulated genes in EGFR-mutant NSCLC cells/tumors accompanied with suppression of lipogenesis. Once resistant, EGFR-mutant NSCLC cell lines possessed elevated levels of mSREBP1, which were resistant to osimertinib modulation. Both genetic and pharmacological inhibition of SREBP1 sensitized osimertinib-resistant cells and tumors to osimertinib primarily through enhancing Bim-dependent induction of apoptosis, whereas enforced expression of ectopic SREBP1 in sensitive EGFR-mutant NSCLC cells compromised osimertinib's cell-killing effects. Collectively, we have demonstrated a novel connection between osimertinib and SREBP1 degradation and its impact on the response of EGFR mutant NSCLC cells to osimertinib and suggested an effective strategy for overcoming acquired resistance to osimertinib, and possibly other EGFR inhibitors, via targeting SREBP1.
引用
收藏
页码:6653 / 6665
页数:13
相关论文
共 44 条
  • [21] Inhibition of lipogenesis and induction of apoptosis by valproic acid in prostate cancer cells via the C/EBPα/SREBP-1 pathway
    Pang, Bo
    Zhang, Juanjuan
    Zhang, Xi
    Yuan, Jihong
    Shi, Yanan
    Qiao, Ling
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2021, 53 (03) : 354 - 364
  • [22] Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer
    Chuncao Xu
    Lei Zhang
    Daifei Wang
    Shiqin Jiang
    Di Cao
    Zhongxiang Zhao
    Min Huang
    Jing Jin
    Cell Death Discovery, 7
  • [23] Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer
    Xu, Chuncao
    Zhang, Lei
    Wang, Daifei
    Jiang, Shiqin
    Cao, Di
    Zhao, Zhongxiang
    Huang, Min
    Jin, Jing
    CELL DEATH DISCOVERY, 2021, 7 (01)
  • [24] Involvement of G-Protein-Coupled Receptor 40 in the Inhibitory Effects of Docosahexaenoic Acid on SREBP1-Mediated Lipogenic Enzyme Expression in Primary Hepatocytes
    On, Seungtae
    Kim, Hyun Young
    Kim, Hyo Seon
    Park, Jeongwoo
    Kang, Keon Wook
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (11)
  • [25] Defective uptake of triglyceride-associated fatty acids in adipose tissue causes the SREBP-1c-mediated induction of lipogenesis
    Wagner, EM
    Kratky, D
    Haemmerle, G
    Hrzenjak, A
    Kostner, GM
    Steyrer, E
    Zechner, R
    JOURNAL OF LIPID RESEARCH, 2004, 45 (02) : 356 - 365
  • [26] Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells
    Li, S.
    Oh, Y-T
    Yue, P.
    Khuri, F. R.
    Sun, S-Y
    ONCOGENE, 2016, 35 (05) : 642 - 650
  • [27] Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells
    S Li
    Y-T Oh
    P Yue
    F R Khuri
    S-Y Sun
    Oncogene, 2016, 35 : 642 - 650
  • [28] Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib
    Gu, Jiajia
    Qian, Luxi
    Zhang, Guojing
    Mahajan, Nupam P.
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Sun, Shi-Yong
    LUNG CANCER, 2020, 150 : 26 - 35
  • [29] Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib
    Gu, Jiajia
    He, Xia
    Mahajan, Nupam P.
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Sun, Shi-Yong
    CANCER RESEARCH, 2019, 79 (13)
  • [30] Silibinin inhibits lipid metabolism by primarily targeting the master regulator sterol response element binding protein 1 (SREBP1) in prostate cancer cells
    Nambiar, Dhanya K.
    Deep, Gagan
    Singh, Rana P.
    Agarwal, Chapla
    Agarwal, Rajesh
    CANCER RESEARCH, 2014, 74 (19)